ViiV Secures Its First New Drug Approval With Tivicay
This article was originally published in The Pink Sheet Daily
Executive Summary
The HIV specialist, a joint venture between GSK, Pfizer and Shionogi, will launch the once-daily integrase inhibitor Tivicay, priced slightly higher than Merck’s Isentress and about on par with Gilead’s Stribild when Tivicay is combined with backbone therapy.
You may also be interested in...
Europe’s CHMP Clears Sofosbuvir, Dolutegravir And Dalamanid
As well as new therapies for hepatitis C, HIV/AIDS and tuberculosis, the EU's CHMP issued a positive opinion on new active substance status for Biogen Idec's oral MS therapy dimethyl fumurate after the panel’s latest meeting.
Roche’s Kadcyla, Bayer’s Xofigo Head Latest Positive Opinions In Europe
GSK’s once-daily combination inhaler Relvar Ellipta along with J&J’s diabetes therapy Invokana, Novo Nordisk’s hemophilia therapy NovoEight and Gilead HIV therapy Vitekta complete the list of six new medicines recommended for approval by the CHMP, Europe’s top scientific advisory panel.
GSK/ChemoCentryx Crohn’s Failure May Sink Hefty Phase III Program
SHIELD-1 failure puts the entire 2,500-patient plus Phase III clinical program in limbo as GSK rethinks its Crohn’s disease approach and partner ChemoCentryx’s stock loses close to half its value.